FDA warns Artnaturals after hand sanitizer tests found benzene and acetaldehyde impurities and inspection found CGMP failures.
What happened
FDA inspected the Gardena, California drug manufacturing facility from February 14 to March 11, 2022. The inspection followed FDA lab testing of a batch of artnaturals Scent Free Hand Sanitizer obtained in U.S. distribution, which found unacceptable levels of benzene, acetaldehyde, and acetal impurities; the company and its contract manufacturer recalled the product and expanded the recall. FDA also found the firm lacked a functioning quality unit, complete batch records, proper drug listing and registration, and could not assure fire-exposed inventory would not be distributed.
What FDA found
The firm had no written procedures establishing a quality unit with authority to approve or reject materials and products, handle complaints and recalls, and investigate problems.
21 CFR 211.22The firm did not keep complete batch production and control records for filling hand sanitizer, including equipment, people, containers, labeling, and yield.
21 CFR 211.188FDA lab testing found unacceptable levels of benzene, acetaldehyde, and acetal impurities in artnaturals Scent Free Hand Sanitizer, making it adulterated.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)The firm did not properly register its establishment or list its drug products with FDA, and its listings did not name it as the repackager, so the products are misbranded.
FD&C Act sections 510(i)(1), 510(j), and 502(o); 21 U.S.C. 360(i)(1), 360(j), and 352(o)The firm's quality unit did not adequately oversee contract manufacturers, including Gordon Laboratories, which FDA had cited for CGMP deficiencies.
21 CFR 211.22; FD&C Act section 501(a)(2)(B)FDA said remaining hand sanitizer inventory possibly exposed to fire, smoke, or temperature extremes must not be salvaged or returned to market without evidence it was not exposed and remains safe.
21 CFR 211.208
What FDA wants
FDA tells the company to respond in writing within 15 working days with corrective actions and remediation plans for its quality unit and documentation, to clarify whether it will resume making drugs for the U.S. market, and to provide a final reconciliation of remaining OTC drug inventory. FDA says it should engage a qualified CGMP consultant if it resumes.
Who should pay attention
- brands that use contract manufacturers for OTC drugs
- retailers and distributors selling hand sanitizer
- companies that repackage or list drug products with FDA
This is a summary. Read the original letter on fda.gov.